Understanding Neuromodulator Formulations in Canada: Botox, Letybo, Dysport, Xeomin, and Nuceiva
In Canada, injectable neuromodulators are classified as Schedule D prescription biologic drugs regulated by Health Canada. While patients and practitioners frequently hear brand names such as Botox, Letybo, Dysport, Xeomin, and Nuceiva, these names refer to distinct pharmaceutical formulations rather than interchangeable generic products.
Understanding how these medications are classified, manufactured, and regulated helps clarify why a medical consultation is required before any treatment plan is determined.
1. Active Ingredients and Non-Proprietary Names
Although all five products belong to the botulinum toxin type A class, Health Canada assigns each formulation a unique non-proprietary (proper) name to reflect differences in their molecular structure, purification methods, and manufacturing processes (1–5):
Botox / Botox Cosmetic (onabotulinumtoxinA) (1)
Dysport / Dysport Aesthetic (abobotulinumtoxinA) (2)
Xeomin / Xeomin Cosmetic (incobotulinumtoxinA) (3)
Nuceiva (prabotulinumtoxinA) (4)
Letybo (letibotulinumtoxinA) (5)
Because biological products are derived from living organisms rather than synthesized chemically, subtle variations in complexing (accessory) proteins and molecular weight exist between manufacturers (1–5). For instance, some formulations retain surrounding complexing proteins during purification, while others undergo further purification to isolate only the active neurotoxin molecule (3).
2. Dosing Units Are Not Interchangeable
A critical pharmacological distinction among Botox, Letybo, Dysport, Xeomin, and Nuceiva is how their potency is measured. Each manufacturer uses a proprietary biological assay to determine the unit potency of its specific product (1–5).
Consequently, units are not universally interchangeable across brands—one unit of Botox is not equivalent to one unit of Dysport, and dosing ratios must never be assumed without reference to official clinical standards (1, 2). Prescribing practitioners calculate dosing independently for each product based on its official Health Canada Product Monograph (1–5).
3. Prescription Status and Regulatory Oversight
In Canada, Botox, Letybo, Dysport, Xeomin, and Nuceiva are strictly regulated prescription medications listed on Health Canada's Prescription Drug List (6). Each holds a unique Drug Identification Number (DIN) issued by Health Canada following a comprehensive review of its safety, quality, and manufacturing standards (6, 7).
Because they are prescription biologics:
They may only be prescribed and administered by qualified, licensed healthcare professionals operating within their provincial scope of practice (1–5).
Individual suitability, contraindications, and potential risks must be evaluated in person by a regulated practitioner prior to administration (1–5).
Speaking with a Healthcare Provider
If you have questions about whether a prescription neuromodulator is appropriate for your individual health profile, book an in-person consultation with a licensed medical practitioner. A qualified provider can review your medical history, discuss potential side effects, and explain which Health Canada-approved options align with your assessment.
References
Health Canada. Product Monograph: BOTOX / BOTOX COSMETIC (onabotulinumtoxinA). Drug Product Database. Government of Canada.
Health Canada. Product Monograph: DYSPORT THERAPEUTIC / DYSPORT AESTHETIC (abobotulinumtoxinA). Drug Product Database. Government of Canada.
Health Canada. Product Monograph: XEOMIN / XEOMIN COSMETIC (incobotulinumtoxinA). Drug Product Database. Government of Canada.
Health Canada. Product Monograph: NUCEIVA (prabotulinumtoxinA). Drug Product Database. Government of Canada.
Health Canada. Product Monograph: LETYBO (letibotulinumtoxinA). Drug Product Database. Government of Canada.
Government of Canada. Food and Drug Regulations (C.R.C., c. 870), Section C.01.044 & Prescription Drug List. Justice Laws Website.
Health Canada. Drug Product Database (DPD) Online Query. Government of Canada.

Comments